

# Manuscript\_R3.docx

---

WORD COUNT

5490

TIME SUBMITTED

09-MAR-2024 09:45AM

PAPER ID

107441951

**Design, statistical optimization, and characterization of Esculin-loaded transliposome nanogel for topical delivery: *In-vitro*, *ex vivo* study and dermatokinetic evaluation**

**Abstract**

The purpose of this study was to prepare and optimise an Esculin-loaded transliposome (ECL-TL) for the dermal administration of ECL for skin cancer treatment. The ECL-TL formulation effectively produced closed lamellar vesicles with *in-vitro* drug release of  $81.28 \pm 2.82\%$  and *ex-vivo* penetration studies showed that had a 2.2-part intensified permeability compared to the conventional preparation. The CLSM data of skin visibly displayed intense permeation of ECL-TL formulated with rhodamine B, equating to the rhodamine B hydroalcoholic solution. The dermatokinetic study suggested that TLs enhance the permeability of the delivery system when topically applied. According to the data, the developed ECL-TL could be an effective drug nano-carrier for the dermal delivery of ECL in treating skin cancer.

**Keywords:** Esculin; Transliposomes; Gel; Dermal; Dermatokinetic

## 1. Introduction

Skin cancer originates from the abnormal growth of cells. This abnormal cell growth primarily results from unrepaired DNA damage in skin cells, which leads to the development of mutations. The delivery systems like, ethosomes, liposomes, niosomes, and nano emulsions are examples of nano-carriers that contain drugs. Through the resolution of several problems, such as drug solubility and instability, dermal delivery reduces drug toxicity and enhances medication efficacy (Verma et al., 2013).

Esculin (ECL) is a herbal drug and one of the Cortex Fraxini's main active ingredients, can serve as a promising medication to prevent inflammatory conditions in humans (Niu et al., 2015). The structure of ECL showed in the Figure 1. This suggests that ECL can potentially treat several inflammatory and oxidative damage-related disorders. The anti-diabetic action of ECL is intimately associated with the amelioration of pancreatic damage, promotion of insulin production and improvement of glucose homeostasis (Li et al., 2022; Kaneko et al., 2003). Furthermore, in 2007, Zhao et al. demonstrated that ECL efficiently inhibited dopamine-induced caspase-3 cleavage, preventing cell death, using the dopamine-induced cytotoxicity model in human neuroblastoma SH-SY5Y cells. Furthermore, this study demonstrated ECL's capability to counteract the over-production of reactive oxygen species, prevent morphological changes in cell nuclei and protect antioxidant enzymes from damage (Zhao et al., 2007). In rat livers, ECL has been shown to scavenge hydroxyl radicals and prevent lipid (LP) peroxidation (Kaneko et al., 2003). ECL exhibits anti-inflammatory properties in mouse models, specifically in zymosan and carrageenan-induced paw oedema cases (Stefanova et al., 1995).

According to Brar et al., 2018, Nanoparticles containing esculin were developed using a method called ionic gelation with a combination of chitosan and okra gum. When

administered, these nanoparticles showed approximately twice the brain targeting capability compared to esculin administered as a plain solution.

The field of transdermal delivery has witnessed a revolutionary breakthrough with the advent of transliposomes. Their robust structure ensures sustained release profiles, enhancing both drug efficacy and patient convenience. The ability to maintain therapeutic levels over extended periods contributes significantly to improved patient adherence and treatment outcomes.

The study aimed to develop a nanogel formulation for treating skin cancer due to the challenges associated with the short half-life, limited therapeutic range, and poor water solubility and absorption of esculin. The formulation optimization process used the Box-Behnken design (BBD) (Jawad, Ali H., et al 2022, Jawad, Ali H., et al 2022).

19

## **2. Material and method**

### **2.1. Materials**

ECL, cholesterol (CLT) and triethanolamine were sourced from “Sigma-Aldrich” whereas Lipoid GmbH provided Lipoid S100. “Sodium cholate (SC) was obtained from Thomas Baker in the United States” and “Carbopol 940 and PEG 400 were acquired from Merck”. Additionally, various other compounds were obtained from “Merck in the United States”.

### **2.2. Formulation of ECL-TL**

For the preparation of ECL-TL formulation, specific quantities of LP, CLT, SC and ECL (1mg/mL) were mixed in a chloroform and ethanol in a ratio of 2:1 v/v in a flask. This mixture was exposed to diluent evaporation using the rotary evaporator for 4 hours. Subsequently, the dehydrated thin film of the LP layer was rehydrated by spinning at 120 revolutions per minute in a pH 7.4 solution for an hour at room temperature. The obtained dispersions were subjected to a 3 minutes sonication process using a probe sonicator.

### **2.3. ECL-TL formulation optimisation utilising BBD software**

The ECL-TL formulation was optimized with the use of BBD software. According to the QbD software, 17 ECL-TL preparations were obtained and analysed. LP (X1), CLT (X2) and SC (X3) were chosen as independent variables, however, the dependent variables that selected were “droplet size (Y1), entrapment efficiency (Y2), and in-vitro release (Y3) (Table 1A)”.

#### 2.4. TL droplet size and polydispersity index (PDI)

ECL-TL's droplet dimension and PDI were measured using an instrument Zetasizer “(Malvern Zetasizer, Nano ZS, UK)” at 25°C ± 1°C. The formulations used in this study were diluted appropriately with saline solution (pH 7.4), and the studies were conducted in triplicate.

#### 2.5. Encapsulated content efficiency

The %EE of the TLs preparation was determined using ultracentrifugation. The free ECL was isolated by centrifugation of 2 ml of ECL-TL at 25000 rpm for 1 hour at 4 °C. The amount of ECL was determined by UV/Vis spectroscopy at 338 nm using buffer solution (pH 7.4) after the recovered supernatant was diluted and filtered (Rehman et al., 2015).

$$\%EE = \frac{(Total\ ECL - ECL\ in\ supernatant)}{Total\ ECL} \times 100$$

#### 2.6. Assessment of *in-vitro* parameters

The final selected proportion of ECL-TLs was introduced into a dialysis pouch, which was subsequently immersed in 50 ml of phosphate buffer (pH 7.4), all at room temperature. At interval of 0.25, 0.5, 1, 2, 4, 6, 12 and 24 hours, One milliliter of the solution was extracted and substituted with an equivalent amount of dissolving medium. A UV spectrophotometer “(UV-1601, Shimadzu, Japan)” was utilized to quantify the content of ECL at 338 nm. (Halayqa & Domańska, 2014; Rehman et al., 2015). The *in-vitro* parameters were assessed using a variety of models (Ahad et al., 2016).

## 2.7. Morphology of ECL-TL

<sup>1</sup> TEM “(CM 200, Philips Briarcliff Manor, NY, USA)” was used to conduct the morphological study of the ECL-TL preparation. The <sup>10</sup> diluted sample was taken on a copper-grid as a tiny droplet, allowed <sup>1</sup> to dry, and then stained using a 1% weight-based PPTA (phosphotungstic acid) solution (Ahad et al., 2018; Siddiqui et al., 2022).

## 2.8. Antioxidant properties

Briefly, <sup>1</sup> 0.5 ml of ECL-TL was dissolved with 0.3 ml of the ethanolic DPPH solution and 3 ml of ethanol. This mixture was let to rest for one hundred minutes in a dark atmosphere. At 517 nm, a spectroscopic analysis was performed to check the colour shift. 0.3 ml of the DPPH solution and 3.5 ml of 70% ethanol made up the control solution. <sup>23</sup> The following equation was used to determine the sample's antioxidant activity (Gupta et al., 2020):

$$\% \text{ antioxidant activity} = \frac{\text{Absorbance of control} - \text{Absorbance of the sample}}{\text{Absorbance of control}} \times 100$$

## 2.9. Preparation of ECL-TL gel

<sup>10</sup> The carbopol 934 (1% w/w) gel was prepared by dispersing in HPLC grade water to ensure an even dispersion. The mixture was left until night to allow carbopol 934 to fully swell. After treating the mixture with 0.1% chlorocresol and 15% w/w PEG 400, triethanolamine was added to adjust the pH. Finally, to create a homogeneous gel formulation, the tailored ECL-TL was added dropwise to the prepared gel while continuously mixing (Ahad et al., 2014; Zakir et al., 2020).

## 2.10. Determination of gel pH and texture

The composition of the ECL-TL <sup>1</sup> gel was measured for pH using a pH meter. A texture analyzer was then employed to evaluate the gel composition's consistency. One hundred milliliter glass beaker containing fifty grams of ECL-TL carbopol-gel was gently filled with the gel, making sure there were no air bubbles and the surface was smooth. The obtained

texture data was examined in order to determine its hardness, consistency, cohesion, and viscosity index (Gupta et al., 2020).

### 2.11. Extrudability

About 20 g of gel were packed tightly into a collapsible tube, which had a clamp attached to prevent retraction. After removing the cap, the gel was squeezed out. The quantity of gel that was squeezed out was gathered and weighed in order to determine the amount that was effectively dispensed.

### 2.12. Spreadability

During the experiment, two batches of standard-sized glass slides were readied. The improved topical gel formulations was placed on one of the slides. The second slide was then positioned atop the gel, effectively sandwiching the gel layer between the two slides, covering a length of 7.5 cm. To establish a thin, uniform layer between the slides, accurately weighed (100 g) of gel was put to the upper slide and spread evenly. The extra gel was carefully removed, and both slides were firmly mounted on a stand to cause the least amount of disruption possible. Carefully, a 20 g weight was placed to the upper slide. The time required for the upper slide to travel 7.5 cm before disengaging from the bottom slide as a result of the weight increase was carefully recorded.

### 2.13. Stability study of ECL-TL gel

The main goal of stability testing was to assess the changes in the quality of a drug as time passed, particularly concerning variations in temperature and relative humidity. In the case of the topical gel preparation, a comprehensive stability investigation was conducted over six months, adhering to the recommendations outlined by the ICH. ECL-TLs were subjected to different conditions, including a humidity room at 30°C/75% RH and 40°C/75% RH. Samples were taken in the 1, 2, 3, and 6 months of the study, and they were examined for changes in pH, homogeneity, color, odor, and viscosity.

#### 2.14. Skin permeation analysis

The membrane in this investigation was produced from excised rat skin, and 1 g of ECL-TL gel was put non-occlusively at the upper (donor) compartment. Phosphate buffer (pH 7.4) was added to the lower (receiver) and continuously shaken at 600 rpm and  $37 \pm 1^\circ\text{C}$  during the experiment (Mura et al., 2009). At various time intervals (0.25, 0.5, 1, 2, 4, 6 and 12 hours), 1 ml sample was withdrawn from the lower compartment through the sampling point and substituted with 1 mL of a fresh solution at each time point. The ECL content was quantified at wavelength 338 nm using UV spectroscopy using buffer solution (pH 7.4) as a medium (Chen et al., 2013; Gupta et al., 2020).

#### 2.15. Assessment of deepness permeation

The confocal laser scanning microscopy (CLSM) was used to assess the formulations' penetration depth. Rat skin was excised and mounted on two separate FDC, served as the substrate for this analysis. After evenly applying ECL-TL gel and a hydroalcoholic solution containing rhodamine B to the skin and the gels were incubated for 8 hours at  $37^\circ\text{C}$ . After study, HPLC grade water was used to rinsed to remove any remaining gel from the skin treated with the hydroalcoholic solution and ECL-TL gel containing rhodamine B. After rinsing, the skin was meticulously sectioned into smaller parts and transferred to a microscope slide, ensuring that the stratum corneum side was facing upward. These prepared samples were then examined using CLSM (Moolakkadath et al., 2018).

#### 2.16. Dermatokinetic study

Consistent with the *in-vitro* skin permeation experiment, the drug concentration within various layers of rat skin was examined by applying the ECL-TL gel to the skin layer that is housed inside the FDC device. However, in this particular experiment, the whole section of skin was detached from the apparatus at different time intervals (Kumar et al., 2023). After cleaning the skin with a saline solution (pH 7.4), it was placed in hot water and left there for



two to four minutes to remove any remaining formulation from the skin. Subsequently, both layers (epidermis and dermis) were meticulously detached using forceps. These detached layers were finely sliced into small parts and placed in a methanol solution (5 ml) for 24 hours to facilitate the extraction of ECL. Subsequently, the resultant methanolic solution was filtered and ECL concentration was quantified using HPLC (Chen et al., 2013).

### 3. Results

#### 3.1. Optimisation of ECL-TL by BBD

The BBD program generated 17 experimental runs, including three-centre-point preparations. Among these runs, the quadratic polynomial technique was identified as the utmost suitable technique that effectively represented the outcomes. The R<sup>2</sup> (coefficient of determination), standard deviation (SD) and coefficient of variation (%CV) values of these three responses have been presented in Table 1B. The influence of these chosen parameters has been visually signified in the 3D graph displayed in Figure 2. Additionally, Figure 3 presents a measurable assessment through the investigational values of the responses and the expected standards.

#### 3.2. Response (Y<sub>1</sub>): Variable influence on the droplet size

The mean vesicle size throughout all 17 tests was 168.56 nm (ranging from 155.5 to 204.5 nm) (as shown in Table 1B).

$$\text{Vesicle size} = +156.02 + 12.35 X_1 + 6.15 X_2 - 3.22 X_3 + 1.92 X_1 X_2 - 0.8250 X_1 X_3 - 0.5750 X_2 X_3 + 15.18 X_1^2 + 11.73 X_2^2 + 11.53 X_3^2$$

The concentration of surfactant had a significant effect on the size of the droplet ( $p < 0.0001$ ), followed by the concentration of the lipid ( $p < 0.0002$ ). The equation mentioned above demonstrates that the two independent responses, LP and CLT, benefit droplet dimensions. Thus, upsurges in the amount of LP and CLT led to a rise in the vesicle size (Mohammed et al., 2013). Accordingly, the SC amount is essential for droplet production, as an increase in the SC amount from 5 to 15 mg decreased the dimension of ECL-TL droplets.

### 3.3. Response (Y<sub>2</sub>): Variable influence on the %EE

The %EE across all 17 tests was 80.14% (ranging from 58.18 to 86.55%), as indicated in Table 1B.

$$\text{Entrapment efficiency} = +85.98 + 3.11 X_1 - 3.57 X_2 + 1.80 X_3 - 0.4000X_1X_2 + 0.0625 X_1X_3 + 0.0500 X_2X_3 - 9.69 X_1^2 - 11.87 X_2^2 - 8.07 X_3^2$$

LP and SC played important roles in influencing the EE. <sup>1</sup> The concentration of surfactant had a significant effect on the size of the droplet ( $p < 0.0001$ ), followed by the concentration of the lipid ( $p < 0.0001$ ). As per the equation above, a positive relationship existed between the quantities of LP and SC and the EE of ECL in TL droplets. Similarly, increasing the LP quantities from 80 to 120 mg improved the EE. This enhancement is primarily attributed to the development of a greater number of TL vesicles, which resulted in larger vesicular domains that provided more space for drug entrapment (Zakir et al., 2020).

CLT was added to the ECL-TLs to enhance vesicle stability by preventing leakage (Ahad et al., 2018). However, according to the equation mentioned above, CLT had an adverse effect on entrapment efficiency. This observation aligns with previous findings (Gilani et al., 2019). The bilayer structure of vesicular membranes can be damaged by high CLT levels, which could due to drug loss (Mohammed et al., 2013).

### 3.4. Response (Y<sub>3</sub>): Variable influence on the *in-vitro* parameter

The *in-vitro* parameter ranged from 56.82 to 83.29% across all 17 formulations, averaging 76.41% (as shown in Table 1B).

$$\text{In-vitro drug release} = +82.50 - 1.98 X_1 - 0.8300 X_2 + 1.74 X_3 - 0.1700 X_1X_2 + 2.61 X_1X_3 + 0.4250 X_2X_3 - 16.04 X_1^2 - 5.27 X_2^2 - 4.21 X_3^2$$

According to the equation above, SC positively influenced *in-vitro* release. In contrast, LPs and CLT had a detrimental impact on *in-vitro* parameters. <sup>1</sup> The concentration of surfactant had

a significant effect on the size of the droplet ( $p < 0.001$ ), followed by the concentration of the lipid ( $p < 0.0003$ ).

ECL-TL containing LP (100 mg), CLT (15 mg) and SC (10 mg) satisfied the formulation requirement. The improved ECL-TL preparation demonstrated a droplet dimension of  $155.5 \pm 2.42$  nm (Figure 4A), and the zeta potential (Figure 4C) value of the optimised formulation was found to be  $-27.95$  mV, entrapment efficiency was determined to be  $85.95 \pm 2.75\%$ , and an *in vitro* release was ascertained to be  $81.28 \pm 2.82\%$ . The results provided by the Design-Expert program in terms of droplet size (156.02 nm), %EE (85.98%) and *in vitro* release (82.50%) were close to the projected values. Furthermore, the improved formulation had a PDI value of 0.271.

### 3.5. Morphology of ECL-TL

The prepared droplets had a well-defined, spherical, and uniformly sized structure, according to the TEM image of the improved ECL-TL preparation (Figure 4B). The vesicle size, as assessed by the Zetasizer device using the DLS technique, exhibited a similar size distribution to that shown in Figure 4A.

### 3.6. *In-vitro* parameters

The results revealed that optimised ECL-CF exhibited a lower percentage of drug release ( $42.43 \pm 1.42\%$ ) compared to optimised ECL-TL ( $88.24 \pm 1.82\%$ ), as depicted in Figure 5A. It demonstrated controlled drug release over a 24-hour period, which closely resembled the release pattern reported in the scientific literature for ECL delivered through liposomes (Elsewedy et al., 2021; Li & Wang, 2017). In contrast, the release pattern of ECL from ECL-CF in an aqueous condition was significantly lower than the confines of the experimental model ( $42.43 \pm 1.42\%$ ). The parameter with the maximum correlation coefficient ( $R^2$ ) was favoured for determining the release mechanism. The Higuchi model exhibited the highest correlation coefficient ( $R^2 = 0.8592$ ), followed by the first-order model ( $R^2 = 0.7862$ ) and the

zero-order model ( $R^2 = 0.6628$ ). The results were found to be statistically significant ( $p > 0.001$ ). Furthermore, the release behaviour of ECL from the optimised ECL-TL was evaluated using the Korsmeyer-Peppas model, resulting in an  $R^2$  value of 0.9329 and an  $n$  value of 0.25. These release of ECL from the optimised ECL-TL follows Fickian-diffusion (Khan et al., 2023).

### 3.7. Antioxidant parameters

Researchers have already shown that ECL has antioxidant properties by successfully preventing LP peroxidation and reducing the generation of free radicals (Saraswati et al., 2013). This study compared the enhanced ECL-TL preparation's antioxidant efficacy to that of an ascorbic acid solution. The ascorbic acid solution exhibited an antioxidant impact of  $91.14 \pm 2.43\%$ , whereas the optimised ECL-TL preparation displayed an antioxidant effect of  $74.2 \pm 2.72\%$ . The results were found to be statistically significant ( $p > 0.001$ ). Furthermore, it was found that the sustained antioxidant effectiveness of ECL simultaneously boosted cellular catalase levels, superoxide dismutase action and glutathione peroxidase, contributing to the inhibition of tumour development (Saraswati et al., 2013).

### 3.8. Extrudability, spreadability, texture and pH of the ECL-TL gel

The gel formulations with good extrudability and spreadability were outperformed by a gel made with carbopol 934 as the gelling agent. It is important to consider the pH of the ECL-TL before applying it topically, particularly if the goal is to treat cancer. However, malignant areas can be identified by their slightly acidic pH (Carvalho et al., 2018). Consequently, the ECL-TL gel preparation's measured pH of  $6.2 \pm 0.4$  meant that it could be applied topically to treat skin cancer. As determined by texture analysis, the ECL-TL gel has a firmness of 101.51 g, a consistency of 650.98 g s, a cohesiveness of -71.05 g and a viscosity index of -298.31 g s. Based on the findings, it can be said that the ECL-TL gel preparation has a consistent

appearance and texture because there are no lumps in the formulation and it has a smooth consistency (Moolakkadath et al., 2019).

### 3.9. Stability testing

The F2 formulation (made with Carbopol 934) underwent stability studies in accordance with ICH regulations because it had superior quality features and was meant to guarantee the drug's quality, safety, and efficacy throughout its shelf life. The topical gel's colour, odour, homogeneity, pH and viscosity did not change after stability testing at 0, 1, 2, 3 and 6 months (Table 2).

### 3.10. Skin permeation study

In the 24-hour timeframe, the cumulative ECL permeation from the ECL-CF was only  $38.57 \pm 2.32\%$ , whereas it increased to  $85.32 \pm 3.35\%$  from the optimised ECL-TL gel (Figure 5B). The results were found to be statistically significant ( $p > 0.001$ ). The increase in skin penetration can be ascribed to the compression of TL via the stratum corneum. In order to enable this kind of penetration, edge activators are essential. The variation in force among the two sides of the skin is susceptible to this type of permeation due to the formation of hydrotaxis. The flexibility of the vesicle shape allows for reversible modifications in the membrane's fluidity, facilitating the movement of vesicles through openings (Bisht et al., 2017).

### 3.11. Skin permeation using CLSM

CLSM analysis revealed that the hydroalcoholic mixture of rhodamine B primarily remained in the upper parts of the skin at a depth of  $15 \mu\text{m}$  (Figure 6A). The inclusion of rhodamine B in the ECL-TL gel resulted in significant absorption and deeper penetration, reaching a depth of  $25 \mu\text{m}$  (Figure 6B). The extremely high fluorescence intensity seen in the skin's central region suggests that the gel formulation avoided the outer layers and instead went deeper into the lower epidermis. In summary, the formulated ECL-TL gel effectively delivered

<sup>2</sup> rhodamine B dye into the inner parts of the skin. This phenomenon could be explained by flaws in the way animal skin packs its LP in the subcutaneous area, which the ECL-TL can take advantage of when it penetrates the skin <sup>2</sup> (Bisht et al., 2017). When applied topically, this <sup>1</sup> designed vesicular LP particle can transdermally transport the encapsulated medication to the subcutaneous region.

### 3.12. Dermatokinetic study

Figure 7 illustrates the relative concentration of ECL in the dermis and epidermis parts of the skin through the application of ECL-CF and ECL-TL gel preparations at different time intermediates, whereas Table 3 provides the statistical analysis using one-factor ANOVA <sup>6</sup> (Zain, Zahirah Mohd, et al. 2023, Suhaimi, Aiman, et al. 2022, Jawad, Ali H., et al. 2022). A <sup>31</sup> difference in the epidermis and dermis of the skin upon administration of ECL-TL and ECL-CF gel preparations demonstrated that the ECL-TL gel resulted in a substantially maximum ECL amount, as assessed by  $C_{\text{Skinmax}}$  and  $AUC_{0-8h}$  <sup>2</sup> (Table 3). The enhanced retention of ECL-TL gel may be attributed to the droplet's ability to split across the skin LP bilayer. In the epidermis, the  $T_{\text{Skinmax}}$  <sup>2</sup> of the ECL-TL gel was similar to that of the ECL-CF gel. According to the results, the ECL amount can be measured 30 minutes after skin application. In contrast to the conventional preparation, ECL-TL application demonstrated rapid drug absorption, with  $C_{\text{max}}$  reaching the dermis and epidermis within 1.5 hours and 2 hours, respectively, after topical application. The ECL concentration gradually decreased until the 8-hour mark, when the drug's concentration remained detectable. The study showed significant value with  $P < 0.0001$ .

## 4. Discussion

The study offers insightful information about the topical delivery effectiveness of the ECL-TL nanogel. In this article we have performed the preparation and optimisation of TLs, <sup>22</sup> in-

*in vitro* drug release, antioxidant studies, skin permeation studies, CLSM and skin kinetic studies and stability studies of the optimized ECL-TL.

With the help of BBD software, optimization of ECL-TL formulation was performed. As increase in LPs and CLT, decreased the entrapment efficiency and increased when amount of SC increased. The ECL-TL formulation vesicles showed a clearly defined, spherical, and uniformly sized structure, as the TEM image verified. Compared to the *in vitro* release exhibited by ECL-CF and ECL-TL displayed 2.1 times increase in terms of drug release. The ECL-TL formulation has a 74.2% antioxidant effect, compared to 91.14% in the ascorbic acid solution. This outcome confirms that ECL-TLs gel has antioxidant properties. The antioxidant efficacy of ECL was found to be unaffected by its integration into TL. Compared to the skin permeation study demonstrated by ECL-CF and ECL-TL showed a 2.2 times increase in drug permeation.

Similarly, compared to the CLSM study using a hydroalcoholic solution and ECL-TL exhibited 1.67 times greater penetration into the skin. The dermatokinetic study suggested that TLs enhance the permeability of the delivery system when topically applied. This finding can be associated with the prior findings from the skin permeation and CLSM parameters, which showed maximum permeability of the ECL-TLs due to their elasticity and the existence of an edge activator.

## 5. Conclusion

In this article, BBD software was utilised to optimise ECL-TL formulations. The improved ECL-TL formulation featured nano-sized vesicles with %EE  $85.95 \pm 2.75\%$ , and the results of *in vitro* drug release revealed that the optimised ECL-CF exhibited a lower percentage of drug release ( $42.43 \pm 1.42\%$ ) compared to optimised ECL-TL ( $88.24 \pm 1.82\%$ ). The cumulative permeation of ECL from the ECL-CF was found  $38.57 \pm 2.32\%$ , whereas it increased to  $85.32 \pm 3.35\%$  from the optimised ECL-TL gel. Our findings from the CLSM

parameter revealed that ECL-TL gel facilitated greater rhodamine B permeability through skin associated with the rhodamine B control liquid. Furthermore, dermatokinetic analysis demonstrated that the ECL-TL gel better absorbed ECL than the ECL-CF gel. Importantly, ECL's antioxidant properties remained unaffected even <sup>11</sup> after incorporation into TL vesicles. TLs' LP-based vesicular system establishes reservoirs within <sup>9</sup> the depth of the skin and distributes the drug gradually over a period, reducing the need for frequent treatments. These results suggest that the developed TL formulation <sup>1</sup> has the potential to be a valuable drug carrier for the topical administration of ECL, particularly in the amelioration of skin cancer.

**Funding:** “This study was also supported via funding from Prince Sattam bin Abdulaziz University, project number (PSAU/2023/R/1444)”.

**Ethical Approval:** “There is no ethical issue”.

<sup>37</sup>  
**Conflicts of Interest:** “The authors declare no conflict of interest.”

**Authors' contributions:** “Abdullah Alshetaili is responsible for the conception and design of the study, Data acquisition, interpretation and conclusion”.

## References

- Ahad, A., Aqil, M., Kohli, K., Sultana, Y., & Mujeeb, M., 2016. The ameliorated longevity and pharmacokinetics of valsartan released from a gel system of ultradeformable vesicles. *Artificial cells, nanomed Biotechnol.* 44, 1457–1463. <https://doi.org/10.3109/21691401.2015.1041638>
- Ahad, A., Aqil, M., Kohli, K., Sultana, Y., Mujeeb, M. 2014. Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. *Exp. Opin. Drug. Deliv.* 11, 1149–1162. <https://doi.org/10.1517/17425247.2014.914027>



- Ahad, A., Raish, M., Ahmad, A., Al-Jenoobi, F. I., & Al-Mohizea, A. M., 2018. Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats. *Eur. J. Pharm. Sci.* 111, 409–417. <https://doi.org/10.1016/j.ejps.2017.10.012>
- Ahad, A., Raish, M., Al-Jenoobi, F. I., & Al-Mohizea, A. M., 2018. Sorbitane Monostearate and Cholesterol based Niosomes for Oral Delivery of Telmisartan. *Current drug delivery*, 15(2), 260–266. <https://doi.org/10.2174/1567201814666170518131934>
- Bisht, D., Verma, D., Mirza, M.A., Anwer, M.K., Iqbal, Z., 2017. Development of ethosomal gel of ranolazine for improved topical delivery: in vitro and ex vivo evaluation. *J. Mol.Liq.* 225, 475-81. <https://doi.org/10.1016/j.molliq.2016.11.114>
- Brar V, Kaur G. Preparation of chitosan okra nanoparticles: optimization and evaluation as Mucoadhesive drug delivery system. *Pharmaceutical Nanotechnology*. 2018 Sep 1;6(3):180-91.
- Carvalho, S.M., Mansur, A.A., Capanema, N.S., et al., 2018., Synthesis and in vitro assessment of anticancer hydrogels composed by carboxymethylcellulose-doxorubicin as potential transdermal delivery systems for treatment of skin cancer. *J Mol Liq* 266, 425-440. <https://doi.org/10.1016/j.molliq.2018.06.085>
- Chen, J., Hu, W., Qu, Y. Q., Dong, J., Gu, W., Gao, Y., Fang, Y., Fang, F., Chen, Z. P., & Cai, B. C., 2013. Evaluation of the pharmacodynamics and pharmacokinetics of brucine following transdermal administration. *Fitoterapia*, 86, 193–201. <https://doi.org/10.1016/j.fitote.2013.03.007>
- Elsawedy, H.S., Al Dhubiab, B.E., Mahdy, M.A., Elnahas, H.M., 2021. Brucine PEGylated Nanoemulsion: In vitro and In vivo Evaluation. *Colloids Surf, A Physicochem Eng Asp.* 608, 125618. doi: 10.1016/j.colsurfa.2020.125618.

- Gilani, S. J., Imam, S. S., Ahmed, A., Chauhan, S., Mirza, M. A., & Taleuzzaman, M., 2019. Formulation and evaluation of thymoquinone niosomes: application of developed and validated RP-HPLC method in delivery system. *Drug Dev. Ind. Pharm.* 45, 1799–1806. <https://doi.org/10.1080/03639045.2019.1660366>
- Gupta, D.K., Aqil, M., Ahad, A., Imam, S.S., Waheed, S., Qadir, A., Iqbal, M.K., Sultana, Y., 2020. Tailoring of berberine loaded transniosomes for the management of skin cancer in mice. *J. Drug. Deliv. Sci. Technol.* 60:102051. <https://doi.org/10.1016/j.jddst.2020.102051>
- Halayqa, M., & Domańska, U., 2014. PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release. *Int. J. Mol. Sci.* 15, 23909–23923. <https://doi.org/10.3390/ijms151223909>
- Jawad AH, Rangabhashiyam S, Abdulhameed AS, Syed-Hassan SS, ALOthman ZA, Wilson LD. Process optimization and adsorptive mechanism for reactive blue 19 dye by magnetic crosslinked chitosan/MgO/Fe<sub>3</sub>O<sub>4</sub> biocomposite. *Journal of Polymers and the Environment.* 2022 Jul;30(7):2759-73.
- Jawad AH, Saber SE, Abdulhameed AS, Reghioua A, ALOthman ZA, Wilson LD. Mesoporous activated carbon from mangosteen (*Garcinia mangostana*) peels by H<sub>3</sub>PO<sub>4</sub> assisted microwave: Optimization, characterization, and adsorption mechanism for methylene blue dye removal. *Diamond and Related Materials.* 2022 Nov 1;129:109389.
- Jawad AH, Sahu UK, Jani NA, ALOthman ZA, Wilson LD. Magnetic crosslinked chitosan-tripolyphosphate/MgO/Fe<sub>3</sub>O<sub>4</sub> nanocomposite for reactive blue 19 dye removal: Optimization using desirability function approach. *Surfaces and Interfaces.* 2022 Feb 1;28:101698.

- Kaneko, T., Tahara, S., & Takabayashi, F., 2003. Suppression of lipid hydroperoxide-induced oxidative damage to cellular DNA by esculetin. *Biol. Pharm. Bull.* 26, 840–844.  
<https://doi.org/10.1248/bpb.26.840>
- Kaneko, T., Tahara, S., & Takabayashi, F., 2007. Inhibitory effect of natural coumarin compounds, esculetin and esculin, on oxidative DNA damage and formation of aberrant crypt foci and tumors induced by 1,2-dimethylhydrazine in rat colons. *Biol. Pharm. Bull.* 30, 2052–2057. <https://doi.org/10.1248/bpb.30.2052>
- Khan, R., Mirza, M. A., Aqil, M., Alex, T. S., Raj, N., Manzoor, N., Naseef, P. P., Saheer Kuruniyan, M., Iqbal, Z., 2023. In Vitro and In Vivo Investigation of a Dual-Targeted Nanoemulsion Gel for the Amelioration of Psoriasis. *Gels.* 9, 112.  
<https://doi.org/10.3390/gels9020112>
- Kumar M, Sharma A, Mahmood S et al., 2023. Franz diffusion cell and its implication in skin permeation studies. *J. Disp. Sci. Technol.* 16:1-4.  
<https://doi.org/10.1080/01932691.2023.2188923>
- Li, C. X., Li, J. C., Lai, J., & Liu, Y., 2022. The pharmacological and pharmacokinetic properties of esculin: A comprehensive review. *Phytother. Res.* 36, 2434–2448.  
<https://doi.org/10.1002/ptr.7470>
- Li, S., & Wang, X. P., 2017. In vitro and in vivo evaluation of novel NGR-modified liposomes containing brucine. *Int. J. Nanomed.* 12, 5797–5804.  
<https://doi.org/10.2147/IJN.S136378>
- Mohammed, N., Rejinold, N. S., Mangalathillam, S., Biswas, R., Nair, S. V., & Jayakumar, R., 2013. Fluconazole loaded chitin nanogels as a topical ocular drug delivery agent for corneal fungal infections. *J. Biomed. Nanotechnol.* 9, 1521–1531.  
<https://doi.org/10.1166/jbn.2013.1647>

- Moolakkadath, T., Aqil, M., Ahad, A., Imam, S. S., Iqbal, B., Sultana, Y., Mujeeb, M., & Iqbal, Z., 2018. Development of transethosomes formulation for dermal fisetin delivery: Box-Behnken design, optimization, in vitro skin penetration, vesicles-skin interaction and dermatokinetic studies. *Artif Cells Nanomed Biotechnol.* 46, 755–765. <https://doi.org/10.1080/21691401.2018.1469025>
- Moolakkadath, T., Aqil, M., Ahad, A., Imam, S. S., Praveen, A., Sultana, Y., Mujeeb, M., Iqbal, Z., 2019. Fisetin loaded binary ethosomes for management of skin cancer by dermal application on UV exposed mice. *Int. J. Pharm.* 560, 78–91. <https://doi.org/10.1016/j.ijpharm.2019.01.067>
- Mura, S., Manconi, M., Sinico, C., Valenti, D., & Fadda, A. M., 2009. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. *Int. J. Pharm.* 380, 72–79. <https://doi.org/10.1016/j.ijpharm.2009.06.040>
- Niu, X., Wang, Y., Li, W., Zhang, H., Wang, X., Mu, Q., He, Z., & Yao, H., 2015. Esculin exhibited anti-inflammatory activities in vivo and regulated TNF- $\alpha$  and IL-6 production in LPS-stimulated mouse peritoneal macrophages in vitro through MAPK pathway. *Int. Immunopharmacol.* 29, 779–786. <https://doi.org/10.1016/j.intimp.2015.08.041>
- Rehman, S. U., Kim, I. S., Kang, K. S., & Yoo, H. H., 2015. HPLC Determination of Esculin and Esculetin in Rat Plasma for Pharmacokinetic Studies. *J Chromatogr. Sci.* 53, 1322–1327. <https://doi.org/10.1093/chromsci/bmv014>
- Saraswati, S., Alhaider, A. A., & Agrawal, S. S., 2013. Anticarcinogenic effect of brucine in diethylnitrosamine initiated and phenobarbital-promoted hepatocarcinogenesis in rats. *Chemico-biological Interactions.* 206, 214–221. <https://doi.org/10.1016/j.cbi.2013.09.012>

- Siddiqui, A., Jain, P., Alex, T. S., Ali, M. A., Hassan, N., Haneef, J., Naseef, P. P., Kuruniyan, M. S., Mirza, M. A., & Iqbal, Z., 2022. Investigation of a Minocycline-Loaded Nanoemulgel for the Treatment of Acne Rosacea. *Pharmaceutics*, 14, 2322. <https://doi.org/10.3390/pharmaceutics14112322>
- Stefanova, Z., Neychev, H., Ivanovska, N., & Kostova, I., 1995. Effect of a total extract from *Fraxinus ornus* stem bark and esculin on zymosan- and carrageenan-induced paw oedema in mice. *J. Ethnopharmacol.* 46, 101–106. [https://doi.org/10.1016/0378-8741\(95\)01233-4](https://doi.org/10.1016/0378-8741(95)01233-4)
- Suhaimi A, Abdulhameed AS, Jawad AH, Yousef TA, Al Duaij OK, ALOthman ZA, Wilson LD. Production of large surface area activated carbon from a mixture of carrot juice pulp and pomegranate peel using microwave radiation-assisted ZnCl<sub>2</sub> activation: An optimized removal process and tailored adsorption mechanism of crystal violet dye. *Diamond and Related Materials.* 2022 Dec 1;130:109456.
- Verma, D., Mirza, M.A., Talegaonkar, S., Ahmed, F.J., Iqbal, Z., 2013. Nanopotential of propolis for revocation of enzyme imbalance in UVB induced cutaneous toxicity in murine model: A preliminary study for chemoprotection of skin cancer. *Drug Deliv. Lett.* 3, 70-7. doi.10.2174/2210304x11303010010
- Zain ZM, Abdulhameed AS, Jawad AH, ALOthman ZA, Yaseen ZM. A pH-sensitive surface of chitosan/sepiolite clay/algae biocomposite for the removal of malachite green and remazol brilliant blue R dyes: Optimization and adsorption mechanism study. *Journal of Polymers and the Environment.* 2023 Feb;31(2):501-18.
- Zakir, F., Ahmad, A., Farooq, U., Mirza, M. A., Tripathi, A., Singh, D., Shakeel, F., Mohapatra, S., Ahmad, F. J., & Kohli, K., 2020. Design and development of a commercially viable in situ nanoemulgel for the treatment of postmenopausal osteoporosis. *Nanomedicine.* 15, 1167–1187. <https://doi.org/10.2217/nnm-2020-0079>

- Zakir, F., Ahmad, A., Farooq, U., Mirza, M. A., Tripathi, A., Singh, D., Shakeel, F., Mohapatra, S., Ahmad, F. J., & Kohli, K., 2020. Design and development of a commercially viable in situ nanoemulgel for the treatment of postmenopausal osteoporosis. *Nanomedicine*. 15, 1167–1187. <https://doi.org/10.2217/nnm-2020-0079>
- Zhao, D. L., Zou, L. B., Lin, S., Shi, J. G., & Zhu, H. B., 2007. Anti-apoptotic effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line. *Neuropharmacol*, 53, 724–732. <https://doi.org/10.1016/j.neuropharm.2007.07.017>

# 19%

SIMILARITY INDEX

### PRIMARY SOURCES

- |   |  |                 |
|---|--|-----------------|
| 1 | <a href="http://www.mdpi.com">www.mdpi.com</a><br>Internet   | 297 words — 7%  |
| 2 | <a href="http://link.springer.com">link.springer.com</a><br>Internet   | 117 words — 3%  |
| 3 | Abdul Qadir, Shehla Nasar Mir Najib Ullah, Dipak Kumar Gupta, Nausheen Khan, Musarrat Husain Warsi, Mehnaz Kamal. "Combinatorial drug-loaded quality by design adapted transliposome gel formulation for dermal delivery: In vitro and dermatokinetic study", <i>Journal of Cosmetic Dermatology</i> , 2023<br>Crossref                          | 47 words — 1%   |
| 4 | Praveen Sekar, Vignesh Natarajan, Nivetha Shanmugam, Thilagasundari Kandasamy. "Preliminary phytochemical analysis, formulation and evaluation of anti-inflammatory potential of the formulated gel obtained from an Ethanolic leaves extract of Lour", <i>International Journal of Pharmaceutical Chemistry and Analysis</i> , 2023<br>Crossref | 28 words — 1%   |
| 5 | <a href="http://www.tandfonline.com">www.tandfonline.com</a><br>Internet   | 22 words — < 1% |
| 6 | Nabil A. Alhakamy, Hibah M. Aldawsari, Javed Ali, Dipak K. Gupta et al. "Brucine-loaded  | 21 words — < 1% |

transliposomes nanogel for topical delivery in skin cancer: statistical optimization, in vitro and dermatokinetic evaluation", 3 Biotech, 2021

Crossref

7 Sahim Aziz Hazari, Afsana Sheikh, Mohammed A.S. Abourehab, Alaa S. Tulbah, Prashant Kesharwani. "Self-assembled Gallic acid loaded lecithin-chitosan hybrid nanostructured gel as a potential tool against imiquimod-induced psoriasis", Environmental Research, 2023

21 words — < 1%

Crossref

8 [www.researchgate.net](http://www.researchgate.net)

Internet

18 words — < 1%

9 [www.science.gov](http://www.science.gov)

Internet

18 words — < 1%

10 Dipak Kumar Gupta, Mohd. Aqil, Abdul Ahad, Syed Sarim Imam, Ayesha Waheed, Abdul Qadir, Mohammad Kashif Iqubal, Yasmin Sultana. "Tailoring of berberine loaded transiosomes for the management of skin cancer in mice", Journal of Drug Delivery Science and Technology, 2020

17 words — < 1%

Crossref

11 Mohammed Albratty. " Design, optimization, and characterization of -loaded transliposomes for the treatment of Atopic dermatitis: A Box Behnken Design, and tudy ", Journal of Biomaterials Science, Polymer Edition, 2023

17 words — < 1%

Crossref

12 [www2.mdpi.com](http://www2.mdpi.com)

Internet

16 words — < 1%

13 Rajasekaran Aiyalu, Arulkumaran Govindarjan, Arivukkarasu Ramasamy. "Formulation and

13 words — < 1%



evaluation of topical herbal gel for the treatment of arthritis in animal model", Brazilian Journal of Pharmaceutical Sciences, 2016

Crossref

- 
- 14 [mdpi-res.com](https://doi.org/10.3390/1405014) 13 words — < 1%  
Internet
- 
- 15 [hdl.handle.net](https://doi.org/10.3390/1405015) 12 words — < 1%  
Internet
- 
- 16 Mahfuz Elmastas, Ibrahim Turkekul, Lokman Ozturk, Ilhami Gulcin, Omer Isildak, Hassan Aboul-Enein. "Antioxidant Activity of Two Wild Edible Mushrooms (*Morchella vulgaris* and *Morchella esculanta*) from North Turkey", *Combinatorial Chemistry & High Throughput Screening*, 2006 11 words — < 1%  
Crossref
- 
- 17 Rios, E.R.V.. "Mechanisms involved in the gastroprotective activity of esculin on acute gastric lesions in mice", *Chemico-Biological Interactions*, 20101006 11 words — < 1%  
Crossref
- 
- 18 [www.eurchembull.com](https://doi.org/10.3390/1405018) 11 words — < 1%  
Internet
- 
- 19 Afsana Sheikh, Sahim Aziz Hazari, Nagashekhara Molugulu, Saad Ali Alshehri et al. "Hyaluronic acid engineered gallic acid embedded chitosan nanoparticle as an effective delivery system for treatment of psoriasis", *Environmental Research*, 2023 10 words — < 1%  
Crossref
- 
- 20 Thasleem Moolakkadath, Mohd. Aqil, Abdul Ahad, Syed Sarim Imam, Arshiya Praveen, Yasmin 10 words — < 1%

Sultana, Mohd Mujeeb, Zeenat Iqbal. "Fisetin loaded binary ethosomes for management of skin cancer by dermal application on UV exposed mice", International Journal of Pharmaceutics, 2019

Crossref

21 ijper.org

Internet

10 words — < 1%

22 Acharya, Ankit. "Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents", Rajiv Gandhi University of Health Sciences (India), 2023

ProQuest

9 words — < 1%

23 Xiaomin Cao, Kaixin Shi, Yang Xu, Peipei Zhang, Hongyan Zhang, Siyi Pan. "Integrated metabolomics and network pharmacology to reveal antioxidant mechanisms and potential pharmacological ingredients of citrus herbs", Food Research International, 2023

Crossref

9 words — < 1%

24 dokumen.pub

Internet

9 words — < 1%

25 Linlin Zhang, Qingxuan Xie, Xiaofang Li. "Esculetin: A review of its pharmacology and pharmacokinetics", Phytotherapy Research, 2021

Crossref

8 words — < 1%

26 Malleswara Rao Peram, Sunil Jalalpure, Vijay Kumbhar, Sachin Patil, Sumit Joshi, Kishore Bhat, Prakash Diwan. " Factorial design based curcumin ethosomal nanocarriers for the skin cancer delivery: evaluation ", Journal of Liposome Research, 2019

Crossref

8 words — < 1%

---

27 Mohammad Kashif Iqubal, Ashif Iqubal, Hasib Anjum, Madan Mohan Gupta, Javed Ali, Sanjula Baboota. "Determination of in vivo virtue of dermal targeted combinatorial lipid nanocolloidal based formulation of 5-fluorouracil and resveratrol against skin cancer", International Journal of Pharmaceutics, 2021

Crossref

8 words — < 1%

---

28 Mohammed F. Aldawsari, Mohammad Azhar Kamal, Mohamed F. Balaha, Talha Jawaid et al. "Optimized Ribociclib nanostructured lipid carrier for the amelioration of skin cancer: Inferences from ex-vivo skin permeation and dermatokinetic studies", Saudi Pharmaceutical Journal, 2024

Crossref

8 words — < 1%

---

29 Neda Bavarsad, Abbas Akhgari, Somayeh Seifmanesh, Anayatollah Salimi, Annahita Rezaie. "Statistical optimization of tretinoin-loaded penetration-enhancer vesicles (PEV) for topical delivery", DARU Journal of Pharmaceutical Sciences, 2016

Crossref

8 words — < 1%

---

30 Pooja Jain, Mohamad Taleuzzaman, Chandra Kala, Dipak Kumar Gupta, Asad Ali, Mohammed Aslam. "Quality by design (Qbd) assisted development of phytosomal gel of aloe vera extract for topical delivery", Journal of Liposome Research, 2020

Crossref

8 words — < 1%

---

31 [export.arxiv.org](https://export.arxiv.org)

Internet

8 words — < 1%

---

32 [rcastoragev2.blob.core.windows.net](https://rcastoragev2.blob.core.windows.net)

Internet

8 words — < 1%

33 Internet 8 words — < 1%

34 "Design of Experiments for Pharmaceutical Product Development", Springer Science and Business Media LLC, 2021  
Crossref 7 words — < 1%

35 Kainat Nousheen, Fakhar Ud Din, Humzah Jamshaid, Rabia Afza et al. "Metformin HCl-loaded transethosomal gel; development, characterization, and antidiabetic potential evaluation in the diabetes-induced rat model", Drug Delivery, 2023  
Crossref 7 words — < 1%

36 Perwez Alam, Mohd Imran, Dipak Kumar Gupta, Ali Akhtar. "Formulation of Transliposomal Nanocarrier Gel Containing Strychnine for the Effective Management of Skin Cancer", Gels, 2023  
Crossref 7 words — < 1%

37 [www.hindawi.com](http://www.hindawi.com)  
Internet 5 words — < 1%

EXCLUDE QUOTES ON

EXCLUDE SOURCES OFF

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE MATCHES OFF